Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

One of my favourite sessions at any cancer conference is the science symposia, although they go under many different guises and names. At the European Society of Medical Oncology (ESMO) they are known as Special Symposia and conceptually are very similar to Clinical Science Symposia at ASCO.

ESMO 2014Here at these sessions, top thought leaders in the space debate and lecture on key issues of the day. They’re usually packed with information and are well worth attending, even in a hectic schedule.

Interestingly, immuno-oncology has a dominant focus on the program for the first time since I’ve been attending ECCO/ESMO events over the last dozen years or so, demonstrating how quickly it is being assimilated into the scientific and clinical consciousness.  Years ago, I attended a session on autologous cell therapies (ACT) and there were maybe a handful of us in the room.  In Madrid, I doubt if there will be 12 empty seats in the theatre and it will probably be what Pharmaland calls SRO – standing room only.

So what can we learn from the announced sessions this year?

To learn more about our insights and thoughts, you can log-in to read this review.

Posted by 

One Response to “ESMO 2014 Scientific Symposia Preview”

  1. Angela Alexander

    Just a clarification that IBC is not a molecular subset of breast cancer – it is a clinical diagnosis. Biomarker-wise, IBC can be ER+ (~50%), HER2+ (40%) or TNBC (30-35%)….and within TN-IBC, the subsets (for example the 7 Lehmann subtypes) are found at a statistically similar proportions to non-inflammatory TNBCs (Naoto’s lab published this last year).

Comments are closed.

error: Content is protected !!